Results of a long-term (6-month) study of adult patients with PD³

• This clinical trial, analysis, and publication were sponsored by Wyeth Research, Collegeville, PA.
• Relapse of panic disorder was defined as having 2 or more full-symptom (unexpected or situational) panic attacks per week for 2 consecutive weeks or as having been discontinued from the double-blind phase because of loss of effectiveness as determined by the investigators during the study. Average daily dose during the double-blind phase ranged from 165 mg to 171 mg. Trial population (intent-to-treat): 169.
• Patients who completed 12 weeks of open-label treatment with no clinically important ongoing adverse events and who met criteria for responder (1 or fewer full-symptom panic attacks per week during the last 2 weeks of open-label treatment and a CGI-I score of 1 or 2 based on improvement from open-label baseline) during the last 2 weeks of the open-label phase were randomly assigned to receive either EFFEXOR XR or placebo in a double-blind manner for up to an additional 6 months. CGI-I = Clinical Global Impressions—Improvement scale.